Richard Koya to Male
This is a "connection" page, showing publications Richard Koya has written about Male.
Connection Strength
0.151
-
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012 Aug 15; 72(16):3928-37.
Score: 0.020
-
Immune rejection in a humanized model of murine prostate cancer. Anticancer Res. 2010 Feb; 30(2):409-14.
Score: 0.017
-
mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors. J Immunother Cancer. 2025 Mar 25; 13(3).
Score: 0.012
-
WHSC1/NSD2 regulates immune infiltration in prostate cancer. J Immunother Cancer. 2021 02; 9(2).
Score: 0.009
-
Gelsolin inhibits apoptosis by blocking mitochondrial membrane potential loss and cytochrome c release. J Biol Chem. 2000 May 19; 275(20):15343-9.
Score: 0.009
-
Measurement and Quantitative Characterization of Whole-Body Pharmacokinetics of Exogenously Administered T Cells in Mice. J Pharmacol Exp Ther. 2019 03; 368(3):503-513.
Score: 0.008
-
Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants. Bone Marrow Transplant. 1998 May; 21(9):923-6.
Score: 0.007
-
Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014 May 01; 20(9):2457-65.
Score: 0.006
-
CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res. 2014 May 01; 20(9):2424-32.
Score: 0.006
-
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014 Jan; 4(1):80-93.
Score: 0.005
-
Natural killer T cells in advanced melanoma patients treated with tremelimumab. PLoS One. 2013; 8(10):e76829.
Score: 0.005
-
Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov. 2013 Apr; 3(4):418-29.
Score: 0.005
-
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2013 Mar; 123(3):1371-81.
Score: 0.005
-
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov. 2012 May; 2(5):414-24.
Score: 0.005
-
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012 Mar 06; 3:724.
Score: 0.005
-
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012 Jan 19; 366(3):207-15.
Score: 0.005
-
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res. 2011 Jun 15; 17(12):4101-9.
Score: 0.005
-
Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One. 2010 Sep 15; 5(9):e12711.
Score: 0.004
-
Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One. 2010 Jul 22; 5(7):e11726.
Score: 0.004
-
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med. 2009 May 20; 7:35.
Score: 0.004
-
Frequent expression of new cancer/testis gene D40/AF15q14 in lung cancers of smokers. Br J Cancer. 2002 Jun 05; 86(11):1757-62.
Score: 0.002
-
Gelsolin functions as a metastasis suppressor in B16-BL6 mouse melanoma cells and requirement of the carboxyl-terminus for its effect. Int J Cancer. 2001 Sep; 93(6):773-80.
Score: 0.002
-
Chromosomal assignment of a novel human gene D40. Nucleic Acids Symp Ser. 1999; (42):71-2.
Score: 0.002